Latest News and Press Releases

BOSTON, MASSACHUSETTS, May 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel antiviral therapies, today announced...

Pleco Therapeutics announces positive FDA feedback on PTX-252, supporting IND pathway for its novel AML treatment.

Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...

Dublin, Jan. 30, 2025 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" has been added to ResearchAndMarkets.com's offering. The US is the...

Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...

Dublin, April 02, 2024 (GLOBE NEWSWIRE) -- The "Growth Opportunities in Drug Discovery and Early Development Outsourcing Services" report has been added to ResearchAndMarkets.com's offering. The...

Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" has been added to ResearchAndMarkets.com's offering. The US is the...

Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3.

Dublin, Nov. 23, 2023 (GLOBE NEWSWIRE) -- The "CP101 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This "CP101 Emerging Drug Insight...

Dublin, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...